148 related articles for article (PubMed ID: 16133365)
41. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
42. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
[TBL] [Abstract][Full Text] [Related]
43. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
44. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
45. Collision carcinoma of the residual cervical esophagus 27 years after esophageal cancer surgery.
Naritaka Y; Ogawa K; Shimakawa T; Wagatsuma Y; Isohata N; Asaka S; Miyaki A; Shiozawa S; Katsube T; Yoshimatsu K; Aiba M; Ide H
Anticancer Res; 2007; 27(1B):505-11. PubMed ID: 17348434
[TBL] [Abstract][Full Text] [Related]
46. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
47. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
[TBL] [Abstract][Full Text] [Related]
48. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
[TBL] [Abstract][Full Text] [Related]
49. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
50. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
51. Human chorionic gonadotrophin beta expression in malignant Barrett's oesophagus.
Couvelard A; Paraf F; Vidaud D; Dubois S; Vidaud M; Fléjou JF; Degott C
Virchows Arch; 2004 Sep; 445(3):279-84. PubMed ID: 15309632
[TBL] [Abstract][Full Text] [Related]
52. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
[TBL] [Abstract][Full Text] [Related]
53. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
54. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
55. Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance.
Jovov B; Van Itallie CM; Shaheen NJ; Carson JL; Gambling TM; Anderson JM; Orlando RC
Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1106-13. PubMed ID: 17932229
[TBL] [Abstract][Full Text] [Related]
56. Imaging of subsquamous Barrett's epithelium with ultrahigh-resolution optical coherence tomography: a histologic correlation study.
Cobb MJ; Hwang JH; Upton MP; Chen Y; Oelschlager BK; Wood DE; Kimmey MB; Li X
Gastrointest Endosc; 2010 Feb; 71(2):223-30. PubMed ID: 19846077
[TBL] [Abstract][Full Text] [Related]
57. Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
Hermann B; Li Y; Ray MB; Wo JM; Martin RC
Arch Surg; 2005 Dec; 140(12):1204-9; discussion 1209. PubMed ID: 16365243
[TBL] [Abstract][Full Text] [Related]
58. Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas.
Borka K; Kaliszky P; Szabó E; Lotz G; Kupcsulik P; Schaff Z; Kiss A
Virchows Arch; 2007 May; 450(5):549-57. PubMed ID: 17429687
[TBL] [Abstract][Full Text] [Related]
59. Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas.
Paschoud S; Bongiovanni M; Pache JC; Citi S
Mod Pathol; 2007 Sep; 20(9):947-54. PubMed ID: 17585317
[TBL] [Abstract][Full Text] [Related]
60. The prognostic role of claudins in head and neck squamous cell carcinomas.
Nelhűbel GA; Károly B; Szabó B; Lotz G; Kiss A; Tóvári J; Kenessey I
Pathol Oncol Res; 2014 Jan; 20(1):99-106. PubMed ID: 23856835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
